42 results about "EEG HYPSARRHYTHMIA" patented technology

Ventricular tachycardia signals are induced in a living subject. Pace-mapped signals are then obtained from multiple points within the ventricle, and automatically compared numerically with the induced signals. Recognition of a high degree of cross correlation between the induced signals and one or more of the pace-mapped signals identifies arrhythmogenic foci or pathways, which may then be ablated, so that the arrhythmia becomes non-inducible.

A method and a system for detection of an arrhythmia and discrimination between different types of arrhythmia to determine whether to administer an electric shock to the heart, the method comprising monitoring the electrical activity of a beating heart, selecting a number of heart beat intervals that will comprise an analysis segment; determining an instantaneous heart rate for each of the heart beat intervals with the segment; calculating the mean instantaneous heart rate for the segment; determining the variability of the instantaneous heart rates compared to a mean; using a linear combination of the mean and the non-linear value for comparison with a predetermined threshold to discriminate the type of arrhythmia to automatically decide if intervention is indicated.

A system and method for medical premonitory event estimation includes one or more processors to perform operations comprising: acquiring a first set of physiological information of a subject, and a second set of physiological information of the subject received during a second period of time; calculating first and second risk scores associated with estimating a risk of a potential cardiac arrhythmia event for the subject based on applying the first and second sets of physiological information to one or more machine learning classifier models, providing at least the first and second risk scores associated with the potential cardiac arrhythmia event as a time changing series of risk scores, and classifying the first and second risk scores associated with estimating the risk of the potential cardiac arrhythmia event for the subject based on the one or more thresholds.

The disclosure describes techniques for delivering electrical stimulation to decrease the ventricular rate response during an atrial tachyarrhythmia, such as atrial fibrillation. AV nodal stimulation is employed during an atrial tachyarrhythmia episode with rapid ventricular conduction to distinguish ventricular tachyarrhythmia from supraventricular tachycardia and thereby prevent delivering inappropriate therapy to a patient.

In an implantable pacemaker, pacing pulses are delivered to a ventricle in a P-wave synchronous mode as long as no atrial arrhythmia is detected, pacing pulses and a mode switch is made to deliver pacing pulses to the ventricle in a non-P-wave synchronous mode if atrial arrhythmia is detected. From an impedance signal measured in the atrium, atrial distention is determined and, in the non-P-wave synchronous mode, the delivery rate of the pacing pulses is increased to decrease the atrial distention during atrial arrhythmia.

Cardiac monitoring and / or stimulation methods and systems provide for monitoring, diagnosing, defibrillation and pacing therapies, or a combination of these capabilities, including cardiac systems incorporating or cooperating with neuro-stimulating devices, drug pumps, or other therapies. Embodiments relate generally to implantable medical devices employing automated cardiac activation sequence monitoring and / or tracking for arrhythmia discrimination. Embodiments are directed to devices and methods involving sensing a plurality of composite cardiac signals using a plurality of implantable electrodes. A source separation is performed using the sensed plurality of composite cardiac signals and the separation produces one or more cardiac signal vectors associated with one or more cardiac activation sequences that is indicative of ischemia. A change of the one or more cardiac signal vectors is detected using the one or more cardiac signal vectors. Cardiac arrhythmias are discriminated using the one or more cardiac signal vectors.

The present invention relates to novel noncardiotoxic compounds and pharmaceutical compositions useful in the treatment of a variety of disorders including the treatment of depression, allergies, psychoses, cancer and gastrointestinal disorders. In particular, the present invention describes pharmaceutical compositions that mitigate life-threatening arrhythmias such as torsade de pointes. Torsade de pointes is a particular cardiac problem associated with many therapeutic agents and has been implicated as a possible cause of sudden death, particularly in those individuals with a past history of disturbances of cardiac rhythm, myocardial infarction, congenital repolarization abnormalities and cardiac risk factors such as hyperlipidemia and age. This arrhythmia is a variant of paroxysmal ventricular tachycardia associated with a prolonged QTc interval or prominent U waves on the ECG. Torsade de pointes is potentially lethal because it can progress to ventricular fibrillation, life-threatening arrhythmias or precipitate sudden death.

A system for heart performance characterization and abnormality detection includes an interface for receiving sampled data representing an electrical signal indicating electrical activity of a patient heart over multiple heart beat cycles and for receiving a pace signal indicating occurrence of a heart pace pulse applied to the heart. A signal processor uses the received sampled data and pace signal in calculating, a first signal characteristic value comprising a time interval between occurrence of the pace pulse and a cardiac cycle characteristic and a second signal characteristic comprising an average of the time intervals determined over a multiple heart cycles. A comparator compares at least one of the first and second characteristic values with a threshold value to provide a comparison indicator. A patient monitor generates an alert message associated with the threshold in response to the comparison indicator indicating a calculated signal characteristic value exceeds the threshold value.

The present invention provides an improved, Internet-based system that seamlessly collects cardiovascular data from a patient before, during, and after a procedure for EP or an ID. During an EP procedure, the system collects information describing the patient's response to PES and the ablation process, ECG waveforms and their various features, HR and other vital signs, HR variability, cardiac arrhythmias, patient demographics, and patient outcomes. Once these data are collected, the system stores them on an Internet-accessible computer system that can deploy a collection of user-selected and custom-developed algorithms. Before and after the procedure, the system also integrates with body-worn and / or programmers that interrogate implanted devices to collect similar data while the patient is either ambulatory, or in a clinic associated with the hospital. A data-collection / storage module, featuring database interface, stores physiological and procedural information measured from the patient.